

# Krebs Biochemicals & Industries Limited

CIN : L24110AP1991PLC103912



20<sup>th</sup> May, 2019

To,  
The Manager,  
Department of Corporate Relations,  
BSE Limited,  
P J Towers, Dalal Street,  
Fort, Mumbai- 400001.

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai- 400051.

Dear Sir/Madam,

**Sub: Submission of Quick Result.**

We refer to the above mentioned subject, we herewith submit to the Exchange the quick result for the quarter and year ended 31<sup>st</sup> March 2019 as approved by the Board of Directors at their meeting held on 20<sup>th</sup> May, 2019.

This is for the information and records of the Exchange, Please.

Thanking You,

Yours Faithfully,  
For **Krebs Biochemicals & Industries Limited**

  
**Haritha Varanasi**  
Company Secretary

Encl as above

**KREBS BIOCHEMICALS & INDUSTRIES LIMITED**

CIN:L24110AP1991PLC103912



Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031

Corporate Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No: 8, Banjara Hills, Hyderabad - 500 034

**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2019**

(Rs. In lacs)

Sl.No	Particulars	Quarter Ended			Year Ended	
		31.03.2019 (Audited)	31.12.2018 (Unaudited)	31.03.2018 (Audited)	31.03.2019 (Audited)	31.03.2018 (Audited)
	<b>PART - 1</b>					
1	Revenue from Operations					
	a) Net Sales / Income from Operations	851.53	934.87	622.00	3,713.27	2,538.24
	b) Other Operating Income	319.53	199.48	398.55	1,062.53	839.67
2	Other Income	16.22	12.36	15.43	33.06	20.61
3	<b>Total Income from operations (1+2)</b>	<b>1,187.28</b>	<b>1,146.71</b>	<b>1,035.98</b>	<b>4,808.86</b>	<b>3,398.52</b>
4	Expenses					
	a) Cost of Material Consumed	435.18	704.38	534.07	2,099.43	1,712.36
	b) Changes in Inventories of Finished goods, Work-In-Progress	96.31	(109.05)	(171.30)	210.93	(441.83)
	c) Employee Benefits Expenses	387.80	412.63	533.61	1,493.70	1,201.05
	d) Finance Costs	189.73	145.94	142.14	623.80	516.52
	e) Depreciation and Amortisation Expense	118.11	107.37	109.40	440.23	414.97
	f) Other Manufacturing Expenses	380.68	440.85	519.21	1,579.60	1,320.57
	g) Other Expenses	111.43	90.99	86.56	373.41	335.94
	<b>Total Expenses (4)</b>	<b>1,719.24</b>	<b>1,793.11</b>	<b>1,753.69</b>	<b>6,821.10</b>	<b>5,059.58</b>
5	<b>Profit / (Loss) before exceptional items and tax (3±4)</b>	<b>(531.96)</b>	<b>(646.40)</b>	<b>(717.70)</b>	<b>(2,012.24)</b>	<b>(1,661.06)</b>
6	Exceptional Items:					
	a) Depletion in Value of Inventory	-	-	-	-	(95.35)
	b) Amounts Written Off/ written back	11.09	-	(0.89)	11.09	(0.89)
	c) Prior Period Income/(Expenditure)	-	-	(43.59)	-	(40.03)
	d) Profit on sale of Fixed Assets	-	-	14.83	-	14.83
7	<b>Profit / (Loss) before Tax (5 ± 6)</b>	<b>(520.87)</b>	<b>(646.40)</b>	<b>(747.35)</b>	<b>(2,001.15)</b>	<b>(1,782.49)</b>
8	Tax Expense					
	a) Current Tax					
	b) Deferred Tax					
9	<b>Profit / (Loss) for the period (7 ± 8)</b>	<b>(520.87)</b>	<b>(646.40)</b>	<b>(747.35)</b>	<b>(2,001.15)</b>	<b>(1,782.49)</b>
10	Other Comprehensive Income (OCI)					
i	Items that will not be reclassified to profit or Loss	(5.09)	2.50	-	0.20	(33.24)
ii	Income tax relating to items that will not be reclassified to profit or Loss	-	-	-	-	-
iii	Items that will be reclassified to profit or Loss	(47.53)	(29.93)	(76.37)	(132.26)	(109.88)
iv	Income tax relating to items that will be reclassified to profit or Loss	-	-	-	-	-
	Total Other Comprehensive Income (Net of Tax)	(52.62)	(27.43)	(76.37)	(132.06)	(143.12)
11	<b>Total Comprehensive Income for the period(9 ± 10) (Comprising Profit (Loss) and other Comprehensive Income for the period)</b>	<b>(573.49)</b>	<b>(673.83)</b>	<b>(823.71)</b>	<b>(2,133.22)</b>	<b>(1,925.61)</b>
12	Paid-up Equity Share Capital (Face Value Rs. 10/- each)	1663.06	1374.43	1374.43	1663.06	1374.43
13	Other Equity excluding Revaluation Reserve	-	-	-	(1,986.27)	(2,046.65)
14	<b>Earning Per Share (of Rs.10/- each) (not Annualised)</b>					
	a) Basic	(3.45)	(4.90)	(5.99)	(12.83)	(14.01)
	b) Diluted	(4.16)	(4.90)	(5.99)	(15.46)	(14.01)
15	Net Worth (including Retained Earnings)	-	-	-	(1,428.91)	(1,777.92)
a)	Debt Service Coverage Ratio	(1.57)	(2.05)	(2.53)	(1.46)	(1.39)
b)	Interest Service Coverage Ratio	(2.00)	(3.46)	(4.34)	(2.29)	(2.46)
c)	Debt Equity Ratio				(3.52)	(2.91)
	See accompanying notes to the Financial results					

1	The above results have been reviewed by the Audit Committee at its meeting held on 20th May,2019 and approved by the Board of Directors of the Company at its meeting held on 20th May,2019.		
2	The Company is operating in one segment only hence no segment results have been disclosed.		
3	The figures for quarter ended 31st March 2019 and 31st March 2018 are the balancing figures between the audited figures for the full financial year and the reviewed year-to-date figures up to the third quarter of the respective financial years. Figures for the corresponding previous period have been regrouped/reclassified wherever necessary, to make them comparable.		
4	Revenue for the quarter ended 31st March,2018 is net of Goods and Service Tax (GST) which is applicable from 1st July 2017, However, revenue for the periods up to 30th June 2017 is inclusive of VAT, Service Tax and excise duty. Accordingly, revenue for the year ended 31st March 2019 is not comparable with the previous year ended 31 st March 2018.		
5	The company had made allotment of 28,86,300 Nos of shares towards right issue on 25.03.19 with face value of Rs.10/- each and premium of Rs.76/-each. After right issue the total share capital has been increased to Rs.1663.06 lacs and share premium has been increased to Rs.8054.96 Lacs.		
6	The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015.		
7	Formulae for Computation of ratios are as follows-		
	<table border="0"> <tr> <td style="text-align: right;">Debt Service Coverage Ratio =</td> <td><math>\frac{\text{Earnings before Interest and Tax}}{\text{Interest Expense+Principal Repayments made during the period long term loans}}</math></td> </tr> </table>	Debt Service Coverage Ratio =	$\frac{\text{Earnings before Interest and Tax}}{\text{Interest Expense+Principal Repayments made during the period long term loans}}$
Debt Service Coverage Ratio =	$\frac{\text{Earnings before Interest and Tax}}{\text{Interest Expense+Principal Repayments made during the period long term loans}}$		
	<table border="0"> <tr> <td style="text-align: right;">Interest Service Coverage Ratio =</td> <td><math>\frac{\text{Earnings before Interest and Tax}}{\text{Interest Expense}}</math></td> </tr> </table>	Interest Service Coverage Ratio =	$\frac{\text{Earnings before Interest and Tax}}{\text{Interest Expense}}$
Interest Service Coverage Ratio =	$\frac{\text{Earnings before Interest and Tax}}{\text{Interest Expense}}$		
	<table border="0"> <tr> <td style="text-align: right;">Debt/Equity Ratio =</td> <td><math>\frac{\text{Total Debt}}{\text{Equity}}</math></td> </tr> </table>	Debt/Equity Ratio =	$\frac{\text{Total Debt}}{\text{Equity}}$
Debt/Equity Ratio =	$\frac{\text{Total Debt}}{\text{Equity}}$		
	  Avinash Ravi Managing Director DIN : 01616152		
Place:	Hyderabad		
Date:	20.05.2019		

**KREBS-BIOCHEMICALS & INDUSTRIES LIMITED**

CIN:L24110AP1991PLC103912

Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031

Corp Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No:8, Banjara Hills, Hyderabad - 500 034


**Statement of Assets and Liabilities**


Rs. In Lacs

Particulars	As at 31.03.2019 Audited	As at 31.03.2018 Audited
<b>ASSETS</b>		
<b>Non Current Assets</b>		
(a)Property, Plant and Equipment	9,908.46	9,892.99
(b)Capital Work in Progress	163.45	218.94
(c)Other Intangible Assets	218.29	184.04
(d)Intangible assets under development	184.71	154.53
(e)Financial Assets	145.34	109.90
(f)Other Non Current Assets	518.58	303.33
<b>Total Non Current Assets</b>	<b>11,138.83</b>	<b>10,863.73</b>
<b>Current Assets</b>		
(a) Inventories	896.37	1,172.84
(b) Financial Assets		
(i) Trade Receivables	291.09	32.48
(ii) Cash & Cash Equivalents	1,731.89	41.84
(iii) Other Financial Assets	49.42	33.51
(c)Other Current Assets	128.90	443.19
<b>Total Current Assets</b>	<b>3,097.67</b>	<b>1,723.86</b>
<b>Total Assets</b>	<b>14,236.50</b>	<b>12,587.59</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity Share Capital	1,663.06	1,374.43
(b) Other Equity	(3,091.97)	(3,152.35)
<b>Total Equity</b>	<b>(1,428.91)</b>	<b>(1,777.92)</b>
<b>Liabilities</b>		
<b>Non Current Liabilities</b>		
(a)Financial Liabilities		
(i)Long Term Borrowings	5,022.71	5,166.17
(ii)Other Financial Liabilities	350.47	269.81
(b)Provisions	227.40	220.79
(c)Retirement benefit obligations	176.89	147.53
(d)Other Non Current Liabilities	4,401.79	4,333.04
<b>Total Non Current Liabilities</b>	<b>10,179.26</b>	<b>10,137.35</b>
<b>Current Liabilities</b>		
(a)Financial Liabilities		
(i)Borrowings	-	-
(ii)Trade Payables		
(a) Total outstanding dues of micro and small enterprises	321.79	-
(b) Total outstanding dues of creditors other than micro and small enterprises	1,824.49	1,776.00
(iii)Other Financial Liabilities	-	-
(b)Other Current Liabilities	3,197.23	2,326.71
(c)Provisions	65.59	52.95
(d)Retirement benefit obligations	77.04	72.49
<b>Total Current Liabilities</b>	<b>5,486.15</b>	<b>4,228.15</b>
<b>Total Equity and Liabilities</b>	<b>14,236.50</b>	<b>12,587.59</b>


Place: Hyderabad

Date: 20.05.2019



  
**AVINASH RAVI**  
 Managing Director

DIN: 01616152



## PAVULURI & Co.

CHARTERED ACCOUNTANTS


Plot No.48, Flat No.301,  
Micasa, Phase - I, Kavuri Hills,  
Hyderabad - 500 033.  
Ph : 040-2970 2638 / 2639 / 2640  
Email : pavuluriandco@gmail.com

### INDEPENDENT AUDITOR'S REPORT

#### TO THE BOARD OF DIRECTORS OF KREBS BIOCHEMICALS & INDUSTRIES LIMITED

1. We have audited the accompanying Statement of Financial Results of **KREBS BIOCHEMICALS & INDUSTRIES LIMITED** ("the Company") for the quarter and year ended March 31, 2019 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. This Statement is the responsibility of the Company's Management and is approved by the Board of Directors. The Statement, as it relates to the quarter ended March 31, 2019, has been compiled from the related interim standalone financial statements prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") and as it relates to the year ended March 31, 2019, has been compiled from the related annual financial statements prepared in accordance with Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audits of such interim financial statements and annual financial statements.
3. We conducted our audits in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial controls relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal financial control. An audit also includes evaluating the appropriateness of the accounting



**Branches :**

Flat No : 301, Block C, Green City Towers, Green City Township, Near Export Apparel Park, **Visakhapatnam** - 530049.  
Flat No.: 504, Madhu Towers, Srinivasa Nagar Bank Colony, **Vijayawada** - 520008, Ph : 0866-2545418



## PAVULURI & Co.

CHARTERED ACCOUNTANTS

Plot No.48, Flat No.301,  
Micasa, Phase - I, Kavuri Hills,  
Hyderabad - 500 033.  
Ph : 040-2970 2638 / 2639 / 2640  
Email : pavuluriandco@gmail.com

policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our audit opinion.

4. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
- is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016; and
  - gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the loss, total comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2019.

For Pavuluri & Co  
Chartered Accountants  
(Firm's Regn No: 012194s)

  
CA.N.Rajesh  
Partner

M.No: 223169



Place: Hyderabad  
Date: May 20, 2019

**Branches :**

Flat No : 301, Block C, Green City Towers, Green City Township, Near Export Apparel Park, Visakhapatnam - 530049.  
Flat No.: 504, Madhu Towers, Srinivasa Nagar Bank Colony, Vijayawada - 520008, Ph : 0866-2545418

# Krebs Biochemicals & Industries Limited

CIN : L24110AP1991PLC103912



20<sup>th</sup> May 2019

To,

Listing Department  
BSE Limited  
P J Towers, Dalal Street,  
Fort Mumbai- 400001.

Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400051.

Dear Sir/Madam,


**Sub: Declaration Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for unmodified opinion**

## DECLARATION FOR UNMODIFIED OPINION

We hereby declare that, the Statutory Auditors of the Company M/s Pavuluri & Co., Chartered Accountants, (Firm Reg No.012194S) have issued an Audit Report with unmodified opinion on Standalone Financial Results for the quarter & year ended 31<sup>st</sup> March 2019.

Yours Faithfully,

For Krebs Biochemicals & Industries Limited

  
Avinash Ravi  
Managing Director  
(DIN-01616152)

